{
  "id": 12954754,
  "title": "Raymond James initiates Nektar stock coverage with Market Perform",
  "url": "https://urgent.news/2026/10/08/raymond-james-initiates-nektar-stock-coverage-with-market-perform",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T20:58:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/raymond-james-initiates-nektar-stock-coverage-with-market-perform-93CH-4939826"
  },
  "original_language": "en",
  "account": "Raymond James began monitoring Nektar Therapeutics (NKTR) on Tuesday, rating the biotech company's stock as Market Perform. The focus of Nektar's research is on their lead asset, rezpegaldesleukin, an IL-2 Treg stimulator now in late-phase development for autoimmune conditions. Analyst Thomas Deal issued the coverage initiation report. The stock is currently priced at $40.80 with a market capitalization of $1.39 billion, although it has fallen 46% over the last six months. InvestingPro analysis indicates the company may be overvalued relative to its Fair Value, appearing on the Most Overvalued list. A notable concern is the rapid cash burn, as levered free cash flow stands at -$235 million. Investors can obtain more in-depth information through the Pro Research Report for NKTR and over 1,400 other US equities. Nektar Therapeutics reported a smaller-than-expected loss in its second-quarter 2026 earnings, posting a loss of $1.23 per share, beating analyst estimates of a $2.00 per share loss. However, revenue fell short of expectations, with $10.13 million reported compared to the projected $10.38 million. Despite the earnings beat, investors remain cautious due to the company's long path to commercializing its products. Nektar was recently awarded $90 million in a jury verdict against Eli Lilly for breach of contract and implied covenant of good faith and fair dealing, stemming from their earlier collaboration on rezpegaldesleukin. H.C. Wainwright maintained a Buy rating on Nektar Therapeutics, with a price target of $185.00, following the company's positive clinical trial data from the Phase 2b REZOLVE-AA study in alopecia areata.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Raymond James initiates Kymera Therapeutics stock coverage with outperform rating",
        "url": "https://urgent.news/2026/10/08/raymond-james-initiates-kymera-therapeutics-stock-coverage-with",
        "published": "2026-10-08T21:38:50.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}